Physician profile
Amit Patel
NPI 1528401676
$11,115.56
in general payments reported to CMS, 2019-2025
27 companies · $1,797 in 2025
The $1,797 reported for 2025 was more than what 88% of Otolaryngology providers received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $635 · 2020: $444 · 2021: $269 · 2022: $1,403 · 2023: $836 · 2024: $5,731 · 2025: $1,797.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,588 · Food and Beverage: $3,777.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,587.50 |
| Food and Beverage | $3,776.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $5,329.12 | 2020-2025 | Inspire |
| Stryker Corporation | $802.71 | 2019-2025 | Scopis Ent |
| Medtronic, INC. | $634.09 | 2022-2024 | Propel |
| Genzyme Corporation | $542.69 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $539.88 | 2020-2025 | Dupixent |
| Glaxosmithkline, LLC. | $485.96 | 2021-2025 | Nucala |
| Aerin Medical INC. | $452.64 | 2019-2025 | |
| Integra Lifesciences Corporation | $411.72 | 2024-2025 | Trudi Probe, Inspira Air, Acclarent Aera |
| Acclarent, INC | $300.43 | 2021-2024 | Trudi Nav Cable, Acclarent Aera, Acclarent Navwire |
| Genentech USA, INC. | $214.39 | 2019-2024 | Xolair |
| Novartis Pharmaceuticals Corporation | $200.57 | 2021-2025 | |
| Medtronic USA, INC. | $197.13 | 2019 | |
| Kaleo, INC. | $190.23 | 2019-2024 | Auvi-Q |
| Smith+Nephew, INC. | $181.21 | 2019-2025 | Tula, Coblation |
| Optinose US, INC. | $111.83 | 2020-2025 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $101.73 | 2021-2025 | Tezspire, Airsupra, Fasenra |
| Penumbra, INC. | $92.59 | 2025 | Penumbra System |
| Ars Pharmaceuticals Operations, INC. | $66.58 | 2025 | Neffy |
| Boston Scientific Corporation | $53.77 | 2019-2022 | |
| Hikma Pharmaceuticals USA | $52.69 | 2023-2025 | Ryaltris |
| Intersect Ent, INC. | $35.30 | 2019-2020 | |
| Ambu INC. | $24.20 | 2022 | |
| Alk-Abello, INC | $21.68 | 2020 | |
| Hologic Sales and Service, LLC | $21.40 | 2023 | Coolseal Generator |
| Phadia US INC. | $20.11 | 2024 | Immunocap |
| Olympus America INC. | $16.22 | 2022 | |
| Neurent Medical Limited | $14.69 | 2025 | Neuromark System, Neuromark Radiofrequency Console |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amit Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.